Key result
Targeting necroptosis via RIPK1 and RIPK3 inhibitors emerges as a novel cardiovascular disease therapy.
Answers are grounded in this paper and cite their sources.
Cardiovascular diseases, including peripheral arterial and venous disease, myocardial infarction, and stroke, are the number one cause of death worldwide annually. In the last 20 years, the role of necroptosis, a newly identified form of regulated necrotic cell death, in cardiovascular disease has come to light. Specifically, the damaging role of two kinase proteins pivotal in the necroptosis pathway, Receptor Interacting Protein Kinase 1 (RIPK1) and Receptor Interacting Protein Kinase 3 (RIPK3), in cardiovascular disease has become a subject of great interest and importance. In this review, we provide an overview of the current evidence supporting a pathologic role of RIPK1 and RIPK3 in cardiovascular disease. Moreover, we highlight the evidence behind the efficacy of targeted RIPK1 and RIPK3 inhibitors in the prevention and treatment of cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
DeRoo et al. (2020) conducted a review in Cardiovascular disease. Targeted RIPK1 and RIPK3 inhibitors was evaluated. Targeted RIPK1 and RIPK3 inhibitors and their role in necroptosis are reviewed for the prevention and treatment of cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: